Targeting endoplasmic reticulum stress to attenuate cisplatin resistance in non-small cell lung cancer
Medical Oncology · 2026
DOI: 10.1007/s12032-026-03369-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medical Oncology, 2026. Verfasst von Semahat Celikten und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Biology, Faculty of Medicine, Ege University, Izmir, Türkiye. Hauptthemen laut MEDLINE: Cisplatin, Carcinoma, Non-Small-Cell Lung, Drug Resistance, Neoplasm, Lung Neoplasms. Die Arbeit nennt 39 Literaturangaben. Gefördert von: Ege University Scientific Research Projects Coordination.
Abstract (Originalsprache)
Cisplatin-based chemotherapy remains a cornerstone of treatment for advanced non-small cell lung cancer (NSCLC); however, the emergence of chemoresistance severely limits its clinical efficacy. Endoplasmic reticulum (ER) stress and adaptive unfolded protein response (UPR) have been implicated in cancer cell survival and therapy resistance, highlighting modulation of this signalling as a potential therapeutic strategy. In this study, we investigated whether pharmacological induction of endoplasmic reticulum stress via sarco/endoplasmic reticulum Ca²⁺-ATPase (SERCA) inhibition could attenuate cisplatin resistance in NSCLC. Using parental and cisplatin-resistant cell lines, we demonstrate that thapsigargin induces transcriptional responses consistent with endoplasmic reticulum stress, characterised by dynamic regulation of GRP78, PERK, XBP1, and ATF4 mRNA expression. Notably, thapsigargin pre-treatment significantly reduced cisplatin IC₅₀ values and decreased resistance indices in resistant cells, indicating attenuation of the resistant phenotype. In addition, SERCA inhibition enhanced apoptotic cell death in selected models and markedly suppressed clonogenic survival and migratory capacity across all cell lines examined. Distinct UPR-related transcriptional patterns were observed between parental and resistant cells, suggesting adaptive remodelling of ER stress signalling during acquisition of cisplatin resistance. Collectively, these findings identify ER calcium homeostasis as a modifiable determinant of platinum responsiveness and support targeting ER stress pathways as a potential adjunct strategy to improve therapeutic efficacy in chemoresistant NSCLC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Biology, Faculty of Medicine, Ege University, Izmir, Türkiye.
- Department of Medical Biology, Faculty of Medicine, Ege University, Izmir, Türkiye. vldnbozok@gmail.com.
Förderung
- Ege University Scientific Research Projects Coordination
Zitieren
APA
Celikten, S., Yildirim, Z., Aydemir, S., Bara, B., Dogan, E., Eroglu, Z., & Bozok, V. (2026). Targeting endoplasmic reticulum stress to attenuate cisplatin resistance in non-small cell lung cancer. Medical Oncology. https://doi.org/10.1007/s12032-026-03369-5
Vancouver
Celikten S, Yildirim Z, Aydemir S, Bara B, Dogan E, Eroglu Z, et al. Targeting endoplasmic reticulum stress to attenuate cisplatin resistance in non-small cell lung cancer. Medical Oncology. 2026. doi:10.1007/s12032-026-03369-5
BibTeX
@article{Celikten2026,
author = {Celikten, Semahat and Yildirim, Zafer and Aydemir, Sevim and Bara, Busra and Dogan, Eda and Eroglu, Zuhal and Bozok, Vildan},
title = {Targeting endoplasmic reticulum stress to attenuate cisplatin resistance in non-small cell lung cancer},
journal = {Medical Oncology},
year = {2026},
doi = {10.1007/s12032-026-03369-5}
}
EUVIMED